0002064835-26-000049.txt : 20260424 0002064835-26-000049.hdr.sgml : 20260424 20260424163504 ACCESSION NUMBER: 0002064835-26-000049 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: Rule 506(b) provides a "safer harbor" for a private offering FILED AS OF DATE: 20260424 DATE AS OF CHANGE: 20260424 EFFECTIVENESS DATE: 20260424 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Telo Genomics Corp. CENTRAL INDEX KEY: 0001872138 ORGANIZATION NAME: EIN: 000000000 STATE OF INCORPORATION: Z4 FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-581843 FILM NUMBER: 26894868 BUSINESS ADDRESS: STREET 1: 101 COLLEGE STREET, SUITE 200 CITY: TORONTO STATE: A6 ZIP: M5G 1L7 BUSINESS PHONE: 4166738487 MAIL ADDRESS: STREET 1: 101 COLLEGE STREET, SUITE 200 CITY: TORONTO STATE: A6 ZIP: M5G 1L7 D 1 primary_doc.xml X0708 D LIVE 0001872138 Telo Genomics Corp. 1060 QUEBEC STREET VANCOUVER A1 BRITISH COLUMBIA, CANADA V6A 4K8 647-477-9365 CANADA (FEDERAL LEVEL) None None Corporation true John Farlinger 1060 Quebec Street Vancouver A1 BRITISH COLUMBIA, CANADA V6A 4K8 Executive Officer Director Chairman Sabine Mai 331 Beaverbrook Street Winnipeg A2 MANITOBA, CANADA R3N 1M9 Director Promoter John Price 14022 E Fair Pl Centennial CO COLORADO 80111 Executive Officer Ron McGlennen 2240 Legend Drive Golden Valley MN MINNESOTA 55422 Director Biotechnology No Revenues 06b false 2026-03-06 true true true true true true Convertible debt with a conversion price of C$0.05 per common share. Detachable common share purchase warrants, each with an exercise price of C$0.08 and a term of 12 months. false 0 19100 7346 11754 Dollar amounts have been converted from Canadian dollars based on the 0.7346 Bank of Canada daily exchange rate on 3-6-26. Total Remaining to be Sold represents the aggregate exercise price of warrants sold in the United States. false 1 0 0 0 true A portion of the net proceeds may be used for general working capital purposes, including for payments to officers and directors in the ordinary course, but proceeds are not earmarked for such payments false Telo Genomics Corp. /s/ John Price John Price Chief Financial Officer 2026-04-21